B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

87.37 -1.34 (-1.51%)
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,775,964
Open 88.90
Bid (Size) 87.44 (1)
Ask (Size) 87.60 (2)
Prev. Close 88.71
Today's Range 87.07 - 88.98
52wk Range 81.50 - 148.15
Shares Outstanding N/A
Dividend Yield 1.17%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?
Tech stocks began Christmas week with positive momentum, as the Nasdaq 100 rose 0.4% on Monday, building on a 0.7% gain from Friday. The index has now recovered nearly half of the losses sustained... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Better Buy: Eli Lilly or Novo Nordisk?
Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results. 
Via The Motley Fool

Performance

YTD
-14.44%
-14.44%
1 Month
-16.44%
-16.44%
3 Month
-30.35%
-30.35%
6 Month
-40.53%
-40.53%
1 Year
-14.91%
-14.91%

More News

Read More
Novo Nordisk Rises 5% In Premarket As Analyst Dismisses Friday's 17% Plunge As Market Overreaction
Via Benzinga
What Analysts Are Saying About Novo Nordisk Stock
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Via Benzinga
Topics Economy
Exposures Interest Rates
Is Merck the Next Big Weight-Loss Stock?
Via The Motley Fool
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Via Benzinga
Exposures Product Safety
MarketBeat Week in Review – 12/16 - 12/20
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Dow Surges Over 600 Points, Gold Jumps 1.5%
Via Benzinga
Topics Stocks
Exposures US Equities
Wall Street Rallies On Soft Inflation Data, Bonds Rebound, Travel Stocks Surge: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
What's Going On With Amgen Stock On Friday?
Via Benzinga
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher
Via Benzinga
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
Via Benzinga
Dow Up 752 Points, Extending Rebound From Dramatic Losses
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Via The Motley Fool
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Via Benzinga
US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Via Investor's Business Daily
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.